Search results
Author(s):
Emer Joyce
Added:
1 week ago
Explore the diagnostic and therapeutic complexities of cardiac sarcoidosis with Prof Emer Joyce.This presentation, part of the comprehensive Cardiomyopathies track, tackles the persistent challenges in cardiac sarcoidosis, emphasizing that despite decades of clinical experience, diagnosis remains the field's greatest hurdle.Prof Joyce explores the heterogeneous clinical phenotypes capable of…
View more
Author(s):
Added:
1 month ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview…
View more
Aldosterone Synthase Inhibitors
Author(s):
Shubh K Patel
,
Hwee Teoh
,
Ahreni Saunthar
,
et al
Added:
3 months ago
Article
Author(s):
C Noah Nilsson
,
Mads Kristian Ersbøll
,
Finn Gustafsson
Added:
1 year ago
Author(s):
Added:
1 year ago
HFSA 24 - We are joined virtually by Dr Sanjiv Shah to discuss the primary results from EMBARK HFpEF (NCT04766892).EMBARK HFpEF is a phase 2a proof-of-concept study assessing the safety, tolerability and preliminary efficacy of mavacamten treatment on myosin biomarkers in patients with heart failure with preserved ejection fractions (HFpEF) and elevated NT-proBNP.Interview Questions:What is the…
View more
Author(s):
Added:
3 months ago
Discover the rapidly evolving therapeutic options transforming outcomes for cardiac amyloidosis patients with Dr Sarah Cuddy.This comprehensive presentation, part of the Cardiomyopathies track, explores the dramatic advances in both TTR and AL amyloidosis treatment over the past decade. Dr Cuddy examines how modern therapeutic approaches have fundamentally shifted survival curves, particularly…
View more
Author(s):
Giorgia Panichella
,
Alberto Aimo
,
Vincenzo Castiglione
,
et al
Added:
4 months ago
Added:
3 months ago
Source:
Radcliffe Cardiology
Two phase 3 trials presented at the European Society of Cardiology Congress 2025 have provided new insights into the role of myosin inhibitors for hypertrophic cardiomyopathy (HCM), with one trial demonstrating superiority over standard care in obstructive HCM and another failing to meet its primary endpoints in the non-obstructive form of the disease.¹˒²The MAPLE-HCM trial found that the cardiac…
View more
Author(s):
Vasvi Singh
Added:
3 months ago
Navigate the diagnostic complexities of cardiac amyloidosis through expert multimodality imaging techniques with Dr Vasvi Singh.This comprehensive presentation, part of the Cardiomyopathies track, addresses the critical role of advanced imaging in diagnosing cardiac amyloidosis. Dr Singh explores the nuanced differences between SPECT and SPECT-CT imaging capabilities, providing practical insights…
View more
Author(s):
Ovidiu Chioncel
Added:
6 months ago
In this short video, Dr Ovidiu Chioncel shares why acute heart failure remains a critical area of focus in cardiology, highlighting the urgent need for improved strategies in diagnosis and management.This conversation sets the stage for his upcoming Special Focus in Cardiac Failure Review (Impact Factor: 4.2) in 2026, which will explore this topic further.
View more
